Hristo V.
- Country
- Bulgaria
- Department
- N/A
Research Overview
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Adults With Active Psoriatic Arthritis: A Phase 3 Extension Study
- Phase 3 Randomized Double-Blind Study of Subcutaneous Sonelokimab in Biologic DMARD-Naive Adults with Active Psoriatic Arthritis
Data & Insights
Has run more than one trial at 181 of 225 partner sites.
Specializations
Autoimmune Conditions
The investigator specializes in treating psoriatic arthritis, with particular focus on developing therapeutic approaches for patients who have not previously received biologic disease-modifying antirheumatic drugs (DMARDs).
- Treatment-naive patient care
- Biologic therapy assessment
- Inflammatory arthritis management
Their research encompasses evaluating novel therapeutic agents for autoimmune joint conditions.
Therapeutic Innovation
The investigator focuses on studying emerging treatments including sonelokimab and zasocitinib for inflammatory joint conditions, exploring various dosing regimens and treatment protocols.
- Novel therapeutic agents
- Treatment optimization
- Comparative efficacy studies
Their work includes evaluation of different therapeutic approaches for optimal patient outcomes.
Clinical Assessment
The investigator specializes in evaluating treatment responses using ACR50 criteria and other clinical measures to assess therapeutic efficacy in inflammatory joint conditions.
- Response assessment protocols
- Safety monitoring
- Treatment effectiveness evaluation
Their expertise includes comprehensive assessment of treatment outcomes in rheumatic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.